Citius Oncology

Citius Oncology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Citius Oncology (CTOR) as of Nov 22, 2026 is 22.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -0.60 % — a change of -3,812.55% (higher).

FCF Conversion

22.18 %

YoY

-3,812.55%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Citius Oncology is 2025 22.18 % . FCF Conversion Rate (FCF/EBITDA) of Citius Oncology was 2024 -0.60 % . It decreases by -3,812.55% higher compared to the previous year.

The Citius Oncology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
0.44 USD
Jan 1, 2023
4.74 USD
Jan 1, 2024
-0.60 USD
Jan 1, 2025
22.18 USD
The Citius Oncology FCF Conversion history
YEARFCF ConversionYoY
22.18 %-3,812.55%
-0.60 %-112.62%
4.74 %+972.69%
0.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

FCF Conversion Rate (FCF/EBITDA) of Citius Oncology is 22.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Citius Oncology changed from -0.60 % to 22.18 %, representing a -3,812.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Citius Oncology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Citius Oncology

All Key Metrics — Citius Oncology